Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;34(11):2461-2498.
doi: 10.1111/jdv.16915.

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations

A Nast  1 , C Smith  2 , P I Spuls  3 , G Avila Valle  1 , Z Bata-Csörgö  4 , H Boonen  5 , E De Jong  6 , I Garcia-Doval  7 , P Gisondi  8 , D Kaur-Knudsen  9 , S Mahil  10 , T Mälkönen  11 , J T Maul  12 , S Mburu  13 , U Mrowietz  14 , K Reich  15 , E Remenyik  16 , K M Rønholt  17 , P G Sator  18 , M Schmitt-Egenolf  19 , M Sikora  20 , K Strömer  21 , O Sundnes  22 , D Trigos  13 , G Van Der Kraaij  3 , N Yawalkar  23 , C Dressler  1
Affiliations

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations

A Nast et al. J Eur Acad Dermatol Venereol. 2020 Nov.

Abstract

This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.

PubMed Disclaimer

References

    1. Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions, Vol. Version 5.1.0 [updated March 2011]: The Cochrane Collaboration. 2011.
    1. Augustin M, Alvaro-Gracia JM, Bagot M et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 2012; 26(Suppl 4): 1-16.
    1. Campanati A, Ganzetti G, Giuliodori K, Molinelli E, Offidani A. Biologic therapy in psoriasis: safety profile. Curr Drug Safety 2016; 11: 4-11.
    1. International Federation of Psoriasis Association. Position Statement of biosimilars - IFPA. 2019; p. 2.
    1. International Federation of Psoriasis Association. IFPA Advocacy Toolkit for UNIVERSAL HEALTH COVERAGE. 2019.

LinkOut - more resources